Cargando…

Reactive intermediates formation and bioactivation pathways of spebrutinib revealed by LC-MS/MS: In vitro and in silico metabolic study

Spebrutinib is a new Bruton tyrosine kinase inhibitor developed by Avila Therapeutics and Celgene. Spebrutinib (SPB) is currently in phase Ib clinical trials for the treatment of lymphoma in the United States. Preliminary in-silico studies were first performed to predict susceptible sites of metabol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alsibaee, Aishah M., Aljohar, Haya I., Attwa, Mohamed W., Abdelhameed, Ali Saber, Kadi, Adnan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361234/ https://www.ncbi.nlm.nih.gov/pubmed/37484253 http://dx.doi.org/10.1016/j.heliyon.2023.e17058

Ejemplares similares

Investigation of Fenebrutinib Metabolism and Bioactivation Using MS(3) Methodology in Ion Trap LC/MS
por: Alsibaee, Aishah M., et al.
Publicado: (2023)

A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation
por: Abdelhameed, Ali S., et al.
Publicado: (2019)

Characterization of reactive intermediates formation in dacomitinib metabolism and bioactivation pathways elucidation by LC-MS/MS: in vitro phase I metabolic investigation
por: Attwa, Mohamed W., et al.
Publicado: (2018)

Sapitinib: reactive intermediates and bioactivation pathways characterized by LC-MS/MS
por: Attwa, Mohamed W., et al.
Publicado: (2019)

Identification of Iminium Intermediates Generation in the Metabolism of Tepotinib Using LC-MS/MS: In Silico and Practical Approaches to Bioactivation Pathway Elucidation
por: Abdelhameed, Ali S., et al.
Publicado: (2020)

LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways
por: Kadi, Adnan A., et al.
Publicado: (2018)

Characterization of Stable and Reactive Metabolites of the Anticancer Drug, Ensartinib, in Human Liver Microsomes Using LC-MS/MS: An in silico and Practical Bioactivation Approach
por: Abdelhameed, Ali S, et al.
Publicado: (2020)

Identification of reactive intermediate formation and bioactivation pathways in Abemaciclib metabolism by LC–MS/MS: in vitro metabolic investigation
por: Kadi, Adnan A., et al.
Publicado: (2019)

Reactive intermediates in copanlisib metabolism identified by LC-MS/MS: phase I metabolic profiling
por: AlRabiah, Haitham, et al.
Publicado: (2019)

Phase I metabolic profiling and unexpected reactive metabolites in human liver microsome incubations of X-376 using LC-MS/MS: bioactivation pathway elucidation and in silico toxicity studies of its metabolites
por: Attwa, Mohamed W., et al.
Publicado: (2020)

LC–MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation
por: Attwa, Mohamed W, et al.
Publicado: (2021)

Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC–MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies
por: Attwa, Mohamed W, et al.
Publicado: (2020)

Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma
por: Attwa, Mohamed W., et al.
Publicado: (2018)

LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay
por: Attwa, Mohamed W, et al.
Publicado: (2020)

Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability
por: Abdelhameed, Ali S., et al.
Publicado: (2019)

A validated LC-MS/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes
por: Attwa, Mohamed W., et al.
Publicado: (2022)

Identification and characterization of in vivo, in vitro and reactive metabolites of vandetanib using LC–ESI–MS/MS
por: Attwa, Mohamed W., et al.
Publicado: (2018)

Development of an LC-MS/MS Method for Quantification of Sapitinib in Human Liver Microsomes: In Silico and In Vitro Metabolic Stability Evaluation
por: Attwa, Mohamed W., et al.
Publicado: (2023)

Development and Validation of a Rapid LC-MS/MS Method for Quantifying Alvocidib: In Silico and In Vitro Metabolic Stability Estimation in Human Liver Microsomes
por: Attwa, Mohamed W., et al.
Publicado: (2023)

Assessment of In Silico and In Vitro Selpercatinib Metabolic Stability in Human Liver Microsomes Using a Validated LC-MS/MS Method
por: Attwa, Mohamed W., et al.
Publicado: (2023)

Validated LC-MS/MS Method for the Quantification of Ponatinib in Plasma: Application to Metabolic Stability
por: Kadi, Adnan A., et al.
Publicado: (2016)

An Ultrafast UPLC–MS/MS Method for Characterizing the In Vitro Metabolic Stability of Acalabrutinib
por: Attwa, Mohamed W., et al.
Publicado: (2023)

Evaluation of Alectinib Metabolic Stability in HLMs Using Fast LC-MS/MS Method: In Silico ADME Profile, P450 Metabolic Lability, and Toxic Alerts Screening
por: Attwa, Mohamed W., et al.
Publicado: (2023)

A New Validated HPLC-MS/MS Method for Quantification and Pharmacokinetic Evaluation of Dovitinib, a Multi-Kinase Inhibitor, in Mouse Plasma
por: AlRabiah, Haitham, et al.
Publicado: (2020)

LC–MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate
por: Amer, Sawsan M., et al.
Publicado: (2017)

Identification and characterization of in silico, in vivo, in vitro, and reactive metabolites of infigratinib using LC-ITMS: bioactivation pathway elucidation and in silico toxicity studies of its metabolites
por: Al-Shakliah, Nasser S., et al.
Publicado: (2020)

A Validated LC–MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation
por: Attwa, Mohamed W., et al.
Publicado: (2021)

Induced in-source fragmentation pattern of certain novel (1Z,2E)-N-(aryl)propanehydrazonoyl chlorides by electrospray mass spectrometry (ESI-MS/MS)
por: Abdelhameed, Ali S, et al.
Publicado: (2013)

Liquid chromatography–tandem mass spectrometry metabolic profiling of nazartinib reveals the formation of unexpected reactive metabolites
por: Abdelhameed, Ali S., et al.
Publicado: (2019)

Rapid LC-MS/MS Bosutinib Quantification with Applications in Metabolic Stability Estimation
por: Attwa, Mohamed W., et al.
Publicado: (2023)

Profiling of in vivo, in vitro and reactive zorifertinib metabolites using liquid chromatography ion trap mass spectrometry
por: Al-Shakliah, Nasser S., et al.
Publicado: (2022)

Development and validation of an HPLC–MS/MS method for the determination of arginine-vasopressin receptor blocker conivaptan in human plasma and rat liver microsomes: application to a metabolic stability study
por: Alrabiah, Haitham, et al.
Publicado: (2018)

Conocarpus lancifolius (Combretaceae): Pharmacological Effects, LC-ESI-MS/MS Profiling and In Silico Attributes
por: Khurm, Muhammad, et al.
Publicado: (2023)

LC, MS(n) and LC–MS/MS studies for the characterization of degradation products of amlodipine
por: Tiwari, Ravi N., et al.
Publicado: (2015)

Fecal metabolite analysis of Japanese macaques in Yakushima by LC-MS/MS and LC-QTOF-MS
por: TSUCHIDA, Sayaka, et al.
Publicado: (2021)

In-Vivo Antidiabetic Activity and In-Silico Mode of Action of LC/MS-MS Identified Flavonoids in Oleaster Leaves
por: Mechchate, Hamza, et al.
Publicado: (2020)

Largazole Pharmacokinetics in Rats by LC-MS/MS
por: Yu, Mingming, et al.
Publicado: (2014)

Application of LC–MS/MS in the Mycotoxins Studies
por: Gámiz-Gracia, Laura, et al.
Publicado: (2020)

Comparison of Flow Injection-MS/MS and LC-MS/MS for the Determination of Ochratoxin A
por: Zhang, Kai
Publicado: (2021)

The LC-MS/MS Identification and Analgesic and Wound Healing Activities of Lavandula officinalis Chaix: In Vivo and In Silico Approaches
por: Slighoua, Meryem, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_27pf4nc5jk0sno8dd0r5ne9nd4